{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:58:30Z","timestamp":1791874710356,"version":"4.3.4"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04508-0","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T18:22:05Z","timestamp":1784658125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Redefining breast cancer: therapeutic opportunities in HER2-low and emerging molecular subtypes"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9794-1390","authenticated-orcid":false,"given":"Abdul","family":"Shadab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramadan I. Kh.","family":"Al-shdefat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"8","key":"4508_CR1","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3390\/jpm11080808","volume":"11","author":"A Burguin","year":"2021","unstructured":"Burguin A, Diorio C, Durocher F. Breast cancer treatments: updates and new challenges. J Personal Med. 2021;11(8):808. https:\/\/doi.org\/10.3390\/jpm11080808.","journal-title":"J Personal Med"},{"issue":"1","key":"4508_CR2","doi-asserted-by":"publisher","first-page":"e1438","DOI":"10.1111\/cbdd.14384","volume":"103","author":"A Singh","year":"2023","unstructured":"Singh A, Mishra R, Mazumder A. Breast cancer and its therapeutic targets: a comprehensive review. Chem Biol Drug Design. 2023;103(1):e1438. https:\/\/doi.org\/10.1111\/cbdd.14384.","journal-title":"Chem Biol Drug Design"},{"key":"4508_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051015","author":"D Eiger","year":"2021","unstructured":"Eiger D, Agostinetto E, Sa\u00fade-Conde R, de Azambuja E. The exciting new field of HER2-low breast cancer treatment. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13051015.","journal-title":"Cancers (Basel)"},{"key":"4508_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1159\/000527391","volume":"17","author":"C Molinelli","year":"2022","unstructured":"Molinelli C, Jacobs F, Marchi\u00f2 C, Pitto F, Cosso M, Spinaci S, et al. HER2-low breast cancer: where are we? Breast Care (Basel). 2022;17:533\u201345. https:\/\/doi.org\/10.1159\/000527391.","journal-title":"Breast Care (Basel)"},{"key":"4508_CR5","doi-asserted-by":"publisher","first-page":"175883592311528","DOI":"10.1177\/17588359231152842","volume":"15","author":"E Nicol\u00f2","year":"2023","unstructured":"Nicol\u00f2 E, Bielo LB, Curigliano G, Tarantino P. The HER2-low revolution in breast oncology: steps forward and emerging challenges. Ther Adv Med Oncol. 2023;15:17588359231152842. https:\/\/doi.org\/10.1177\/17588359231152842.","journal-title":"Ther Adv Med Oncol"},{"key":"4508_CR6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-22-0703","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Curigliano G, Tolaney S. Navigating the HER2-low paradigm in breast oncology: new standards, future horizons. Cancer Discov. 2022. https:\/\/doi.org\/10.1158\/2159-8290.cd-22-0703.","journal-title":"Cancer Discov"},{"key":"4508_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.4143\/crt.2023.1138","volume":"56","author":"S Kang","year":"2024","unstructured":"Kang S, Kim S-B. HER2-low breast cancer: now and in the future. Cancer Res Treat. 2024;56:700\u201320. https:\/\/doi.org\/10.4143\/crt.2023.1138.","journal-title":"Cancer Res Treat"},{"issue":"1","key":"4508_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/cancers15010126","volume":"15","author":"H Zhang","year":"2022","unstructured":"Zhang H, Peng Y. Current biological, pathological and clinical landscape of HER2-low breast cancer. Cancers. 2022;15(1):126. https:\/\/doi.org\/10.3390\/cancers15010126.","journal-title":"Cancers"},{"key":"4508_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112824","author":"E Agostinetto","year":"2021","unstructured":"Agostinetto E, Rediti M, Fimereli D, Debien V, Piccart M, Aftimos P, et al. HER2-low breast cancer: molecular characteristics and prognosis. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13112824.","journal-title":"Cancers"},{"key":"4508_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00301-6","author":"C Denkert","year":"2021","unstructured":"Denkert C, Seither F, Schneeweiss A, Link T, Blohmer J, Just M, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021. https:\/\/doi.org\/10.1016\/s1470-2045(21)00301-6.","journal-title":"Lancet Oncol"},{"key":"4508_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00208-2","author":"F Schettini","year":"2021","unstructured":"Schettini F, Chic N, Bras\u00f3-Maristany F, Par\u00e9 L, Pascual T, Conte B, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021. https:\/\/doi.org\/10.1038\/s41523-020-00208-2.","journal-title":"NPJ Breast Cancer"},{"key":"4508_CR12","doi-asserted-by":"publisher","unstructured":"Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer. Nat Commun. 2023;14. https:\/\/doi.org\/10.1038\/s41467-023-40715-x","DOI":"10.1038\/s41467-023-40715-x"},{"key":"4508_CR13","doi-asserted-by":"publisher","first-page":"7496","DOI":"10.1038\/s41467-023-43324-w","volume":"14","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Gupta H, Hughes M, Files J, Strauss S, Kirkner G, et al. Comprehensive genomic characterization of HER2-low and HER2\u20130 breast cancer. Nat Commun. 2023;14:7496. https:\/\/doi.org\/10.1038\/s41467-023-43324-w.","journal-title":"Nat Commun"},{"key":"4508_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10549-024-07495-4","volume":"209","author":"R Bansal","year":"2024","unstructured":"Bansal R, Adeyelu T, Elliott A, Walker P, Bustos M, Rodriguez E, et al. Genomic and transcriptomic landscape of HER2-low breast cancer. Breast Cancer Res Treat. 2024;209:323\u201330. https:\/\/doi.org\/10.1007\/s10549-024-07495-4.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4508_CR15","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12967-023-04076-9","volume":"21","author":"J Jin","year":"2023","unstructured":"Jin J, Li B, Cao J, Li T, Zhang J, Cao J, et al. Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer. J Transl Med. 2023;21(1):360. https:\/\/doi.org\/10.1186\/s12967-023-04076-9.","journal-title":"J Transl Med"},{"key":"4508_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153774","author":"H-Z Lai","year":"2022","unstructured":"Lai H-Z, Han J, Fu X, Ren Y-F, Li Z, You F. Targeted approaches to HER2-low breast cancer: current practice and future directions. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14153774.","journal-title":"Cancers (Basel)"},{"key":"4508_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.4175","author":"A Prat","year":"2022","unstructured":"Prat A, Bardia A, Curigliano G, Hammond M, Loibl S, Tolaney S, et al. An overview of clinical development of agents for metastatic or advanced breast cancer without ERBB2 amplification (HER2-low). JAMA Oncol. 2022. https:\/\/doi.org\/10.1001\/jamaoncol.2022.4175.","journal-title":"JAMA Oncol"},{"key":"4508_CR18","doi-asserted-by":"publisher","first-page":"175883592311754","DOI":"10.1177\/17588359231175440","volume":"15","author":"C Yang","year":"2023","unstructured":"Yang C, Brezden-Masley C, Joy A, Sehdev S, Modi S, Simmons C, et al. Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm. Ther Adv Med Oncol. 2023;15:17588359231175440. https:\/\/doi.org\/10.1177\/17588359231175440.","journal-title":"Ther Adv Med Oncol"},{"key":"4508_CR19","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/cncr.35205","volume":"130","author":"F Qu","year":"2024","unstructured":"Qu F, Lu R, Liu Q, Wu X, Huang X, Yin Y, et al. Antibody\u2013drug conjugates transform the outcome of individuals with low\u2010HER2\u2010expression advanced breast cancer. Cancer. 2024;130:1392\u2013402. https:\/\/doi.org\/10.1002\/cncr.35205.","journal-title":"Cancer"},{"issue":"4","key":"4508_CR20","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3390\/cancers16040800","volume":"16","author":"B Zimmerman","year":"2024","unstructured":"Zimmerman B, Esteva F. Next-generation HER2-targeted antibody-drug conjugates in breast cancer. Cancers. 2024;16(4):800. https:\/\/doi.org\/10.3390\/cancers16040800.","journal-title":"Cancers"},{"key":"4508_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241311379","author":"Y Qiu","year":"2025","unstructured":"Qiu Y, Shi Y, Chao Z, Zhu X, Chen Y, Lu L. Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status. Ther Adv Med Oncol. 2025. https:\/\/doi.org\/10.1177\/17588359241311379.","journal-title":"Ther Adv Med Oncol"},{"key":"4508_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.breast.2022.10.016","volume":"66","author":"E Rassy","year":"2022","unstructured":"Rassy E, Rached L, Pistilli B. Antibody drug conjugates targeting HER2: clinical development in metastatic breast cancer. Breast. 2022;66:217\u201326. https:\/\/doi.org\/10.1016\/j.breast.2022.10.016.","journal-title":"Breast"},{"key":"4508_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/genes13112065","author":"M Najjar","year":"2022","unstructured":"Najjar M, Manore S, Regua A, Lo H. Antibody-drug conjugates for the treatment of HER2-positive breast cancer. Genes (Basel). 2022. https:\/\/doi.org\/10.3390\/genes13112065.","journal-title":"Genes (Basel)"},{"key":"4508_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104090","author":"I Schlam","year":"2023","unstructured":"Schlam I, Moges R, Morganti S, Tolaney S, Tarantino P. Next-generation antibody-drug conjugates for breast cancer: moving beyond HER2 and TROP2. Crit Rev Oncol Hematol. 2023. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104090.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4508_CR25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.20892\/j.issn.2095-3941.2023.0286","volume":"20","author":"L Dai","year":"2023","unstructured":"Dai L, Li Y-W, Shao Z, Jiang Y. Next-generation antibody\u2013drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer. Cancer Biol Med. 2023;20:689\u201394. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0286.","journal-title":"Cancer Biol Med"},{"issue":"4","key":"4508_CR26","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3390\/ijms23042288","volume":"23","author":"K Lau","year":"2022","unstructured":"Lau K, Tan A, Shi Y. New and emerging targeted therapies for advanced breast cancer. Int J Mole Sci. 2022;23(4):2288. https:\/\/doi.org\/10.3390\/ijms23042288.","journal-title":"Int J Mole Sci"},{"key":"4508_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"S Swain","year":"2022","unstructured":"Swain S, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2022;22:101\u201326. https:\/\/doi.org\/10.1038\/s41573-022-00579-0.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4508_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40364-024-00565-1","volume":"12","author":"K Zhu","year":"2024","unstructured":"Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H. HER2-targeted therapies in cancer: a systematic review. Biomark Res. 2024;12(1):16. https:\/\/doi.org\/10.1186\/s40364-024-00565-1.","journal-title":"Biomark Res"},{"key":"4508_CR29","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jncc.2024.12.008","volume":"5","author":"J Zhao","year":"2025","unstructured":"Zhao J, Zhou Z, Saw P, Song E. Silver jubilee of HER2 targeting: a clinical success in breast cancer. J Natl Cancer Cent. 2025;5:379\u201391. https:\/\/doi.org\/10.1016\/j.jncc.2024.12.008.","journal-title":"J Natl Cancer Cent"},{"key":"4508_CR30","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","volume":"21","author":"J Yoon","year":"2024","unstructured":"Yoon J, Oh D-Y. HER2-targeted therapies beyond breast cancer \u2014 an update. Nat Rev Clin Oncol. 2024;21:675\u2013700. https:\/\/doi.org\/10.1038\/s41571-024-00924-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"4508_CR31","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11864-023-01068-1","volume":"24","author":"C Corti","year":"2023","unstructured":"Corti C, Giugliano F, Nicol\u00f2 E, Tarantino P, Criscitiello C, Curigliano G. HER2-low breast cancer: a new subtype? Curr Treat Options Oncol. 2023;24:468\u201378. https:\/\/doi.org\/10.1007\/s11864-023-01068-1.","journal-title":"Curr Treat Options Oncol"},{"key":"4508_CR32","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2147\/bctt.s366122","volume":"15","author":"Y Shirman","year":"2023","unstructured":"Shirman Y, Lubovsky S, Shai A. HER2-low breast cancer: current landscape and future prospects. Breast Cancer Targets Ther. 2023;15:605\u201316. https:\/\/doi.org\/10.2147\/bctt.s366122.","journal-title":"Breast Cancer Targets Ther"},{"key":"4508_CR33","doi-asserted-by":"publisher","first-page":"2853007","DOI":"10.1155\/2024\/2853007","volume":"2024","author":"G el Haddad","year":"2024","unstructured":"el Haddad G, Diab E, Hajjar M, Aoun M, Mallat F, Zalaquett Z, et al. Insights into the emerging entity of HER2-low breast cancer. Int J Breast Cancer. 2024;2024:2853007. https:\/\/doi.org\/10.1155\/2024\/2853007.","journal-title":"Int J Breast Cancer"},{"key":"4508_CR34","doi-asserted-by":"publisher","DOI":"10.20517\/2394-4722.2023.124","author":"F Esteva","year":"2023","unstructured":"Esteva F, Jaffer S. HER2-low metastatic breast cancer: molecular insights and therapeutic strategies. J Cancer Metastasis Treat. 2023. https:\/\/doi.org\/10.20517\/2394-4722.2023.124.","journal-title":"J Cancer Metastasis Treat"},{"issue":"9","key":"4508_CR35","doi-asserted-by":"publisher","first-page":"8206","DOI":"10.3390\/ijms24098206","volume":"24","author":"M Popovic","year":"2023","unstructured":"Popovic M, Silovski T, Kri\u017ei\u0107 M, Plaveti\u0107 D. HER2 low breast cancer: a new subtype or a trojan for cytotoxic drug delivery? Int J Mole Sci. 2023;24(9):8206. https:\/\/doi.org\/10.3390\/ijms24098206.","journal-title":"Int J Mole Sci"},{"key":"4508_CR36","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4159640","author":"J Jin","year":"2022","unstructured":"Jin J, Li B, Cao J, Li T, Zhang J, Cao J, et al. Evolving perspectives in clinical landscape and molecular characteristics of HER2-low breast cancer and beyond. SSRN Electron J. 2022. https:\/\/doi.org\/10.2139\/ssrn.4159640.","journal-title":"SSRN Electron J"},{"key":"4508_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/medicina6104064","author":"A Shaaban","year":"2025","unstructured":"Shaaban A, Kaur T, Provenzano E. HER2-low breast cancer\u2014current knowledge and future directions. Medicina. 2025. https:\/\/doi.org\/10.3390\/medicina6104064.","journal-title":"Medicina"},{"key":"4508_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1484103","author":"L Zhou","year":"2025","unstructured":"Zhou L, Zhang Y, Zhang J, Wang H, Zhao B, Cai Y, et al. Clinical characteristics and therapeutic direction of HER2 low-expression breast cancer. Front Oncol. 2025. https:\/\/doi.org\/10.3389\/fonc.2025.1484103.","journal-title":"Front Oncol"},{"key":"4508_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4143\/crt.2025.1182","volume":"58","author":"J Koh","year":"2025","unstructured":"Koh J, Im S-A. Redefining HER2 in breast cancer: from conventional positivity to low and ultralow in the new era of antibody-drug conjugates. Cancer Res Treat. 2025;58:15\u201325. https:\/\/doi.org\/10.4143\/crt.2025.1182.","journal-title":"Cancer Res Treat"},{"issue":"16","key":"4508_CR40","doi-asserted-by":"publisher","first-page":"12795","DOI":"10.3390\/ijms24161279","volume":"24","author":"M Franchina","year":"2023","unstructured":"Franchina M, Pizzimenti C, Fiorentino V, Martini M, Ricciardi G, Silvestris N, et al. Low and ultra-low HER2 in human breast cancer: an effort to define new neoplastic subtypes. Int J Mole Sci. 2023;24(16):12795. https:\/\/doi.org\/10.3390\/ijms24161279.","journal-title":"Int J Mole Sci"},{"key":"4508_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.834651","author":"K Venetis","year":"2022","unstructured":"Venetis K, Crimini E, Sajjadi E, Corti C, Guerini-Rocco E, Viale G, et al. HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer. Front Mol Biosci. 2022. https:\/\/doi.org\/10.3389\/fmolb.2022.834651.","journal-title":"Front Mol Biosci"},{"key":"4508_CR42","doi-asserted-by":"publisher","first-page":"103831","DOI":"10.1016\/j.breast.2024.103831","volume":"78","author":"N Fusco","year":"2024","unstructured":"Fusco N, Viale G. The \u201clows\u201d: update on ER-low and HER2-low breast cancer. Breast. 2024;78:103831. https:\/\/doi.org\/10.1016\/j.breast.2024.103831.","journal-title":"Breast"},{"key":"4508_CR43","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.sabcs24-p3-01-25","author":"D Trapani","year":"2025","unstructured":"Trapani D, Deshmukh S, Wu S, Xiu J, Jayachandran P, Lin N, et al. Abstract P3\u201301-25: molecular and immunological characterization of HER2-low, HER2 ultra-low, and HER2-null male breast cancer. Clin Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1557-3265.sabcs24-p3-01-25.","journal-title":"Clin Cancer Res"},{"key":"4508_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2025.105796","author":"Y Gao","year":"2025","unstructured":"Gao Y, Hong R, Wang J, Pang J, Wu S, Liang Z. Molecular and clinicopathological characteristics of invasive breast cancers with HER2-ultralow expression. Hum Pathol. 2025. https:\/\/doi.org\/10.1016\/j.humpath.2025.105796.","journal-title":"Hum Pathol"},{"key":"4508_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-024-01557-3","author":"F Guan","year":"2024","unstructured":"Guan F, Ju X, Chen L, Ren J, Ke X, Luo B, et al. Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer. Diagn Pathol. 2024. https:\/\/doi.org\/10.1186\/s13000-024-01557-3.","journal-title":"Diagn Pathol"},{"key":"4508_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbaf026","author":"J Jin","year":"2025","unstructured":"Jin J, Liu T, Cai M, Zhao M, Guo D, Lv H, et al. Clinical and genomic characteristics of HER2-ultralow breast cancer and implications for T-DXd therapy. Precis Clini Med. 2025. https:\/\/doi.org\/10.1093\/pcmedi\/pbaf026.","journal-title":"Precis Clini Med"},{"key":"4508_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202513086","author":"S Xu","year":"2025","unstructured":"Xu S, Yu K, Liu L, Wang Q, Wu X, Chen Y, et al. Proteogenomic characterization reveals subtype-specific therapeutic potential for HER2-low breast cancer. Adv Sci. 2025. https:\/\/doi.org\/10.1002\/advs.202513086.","journal-title":"Adv Sci"},{"issue":"12","key":"4508_CR48","doi-asserted-by":"publisher","first-page":"100901","DOI":"10.1016\/j.modpat.2025.100901","volume":"38","author":"D Morrar","year":"2025","unstructured":"Morrar D, Brogi E, Schwartz C, Pareja F, Wen H, Ross D. HER2-ultralow breast cancer: incidence, clinicopathologic features and need for refined scoring system. Mod Pathol. 2025;38(12):100901. https:\/\/doi.org\/10.1016\/j.modpat.2025.100901.","journal-title":"Mod Pathol"},{"key":"4508_CR49","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2025-0074-oa","author":"H Rai","year":"2025","unstructured":"Rai H, Slodkowska E, Nofech-Mozes S, Plotkin A, Lu F-I. Clinicopathologic features and genomic profile of human epidermal growth factor receptor 2-low and human epidermal growth factor receptor 2-ultralow invasive breast carcinomas. Arch Pathol Lab Med. 2025. https:\/\/doi.org\/10.5858\/arpa.2025-0074-oa.","journal-title":"Arch Pathol Lab Med"},{"key":"4508_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02047-0","author":"Z Yi","year":"2024","unstructured":"Yi Z, Feng K, Lv D, Guan Y, Shao YF, Xu B. Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer. Signal Transduct Target Ther. 2024. https:\/\/doi.org\/10.1038\/s41392-024-02047-0.","journal-title":"Signal Transduct Target Ther"},{"key":"4508_CR51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-3785","author":"WL Hensing","year":"2023","unstructured":"Hensing WL, Gerratana L, Clifton K, Medford A, Velimirovic M, Shah A, et al. Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer. Clin cancer Res. 2023. https:\/\/doi.org\/10.1158\/1078-0432.ccr-22-3785.","journal-title":"Clin cancer Res"},{"issue":"1","key":"4508_CR52","doi-asserted-by":"publisher","first-page":"100925","DOI":"10.1016\/j.modpat.2025.100925","volume":"39","author":"E Rakha","year":"2025","unstructured":"Rakha E, Tan PH, van Bockstal M, Allison K, Brogi E, Callagy G, et al. International expert consensus recommendations for HER2 reporting in breast cancer: focus on HER2-low and ultralow categories. Modern Pathol. 2025;39(1):100925. https:\/\/doi.org\/10.1016\/j.modpat.2025.100925.","journal-title":"Modern Pathol"},{"key":"4508_CR53","doi-asserted-by":"publisher","first-page":"2","DOI":"10.20517\/cdr.2025.151","volume":"9","author":"JS Roth","year":"2026","unstructured":"Roth JS, Guo H, Chen L, Shen M, Gbadegesin OD, Robey RW, et al. Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters. Cancer Drug Resist. 2026;9:2. https:\/\/doi.org\/10.20517\/cdr.2025.151.","journal-title":"Cancer Drug Resist"},{"key":"4508_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1176309","author":"E Sajjadi","year":"2023","unstructured":"Sajjadi E, Guerini-Rocco E, de Camilli E, Pala O, Mazzarol G, Venetis K, et al. Pathological identification of HER2-low breast cancer: tips, tricks, and troubleshooting for the optimal test. Front Mol Biosci. 2023. https:\/\/doi.org\/10.3389\/fmolb.2023.1176309.","journal-title":"Front Mol Biosci"},{"key":"4508_CR55","doi-asserted-by":"publisher","unstructured":"Morrar D, Brogi E, Schwartz CJ, Pareja F, Wen HY,  Ross DS. Human Epidermal Growth Factor Receptor 2 (HER2)-Ultralow Breast Cancer: Incidence, Clinicopathologic Features, and Need for Refined Scoring System. Mod Pathol. 2025;38(12). https:\/\/doi.org\/10.1016\/j.modpat.2025.100901","DOI":"10.1016\/j.modpat.2025.100901"},{"issue":"1","key":"4508_CR56","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13058-025-02001-0","volume":"27","author":"H Lv","year":"2025","unstructured":"Lv H, Yue J, Zhang Q, Xu F, Gao P, Yang H, et al. Prevalence and concordance of HER2-low and HER2-ultralow status between historical and rescored results in a multicentre study of breast cancer patients in China. Breast Cancer Res\u202f: BCR. 2025;27(1):45. https:\/\/doi.org\/10.1186\/s13058-025-02001-0.","journal-title":"Breast Cancer Res : BCR"},{"issue":"1","key":"4508_CR57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41523-025-00882-0","volume":"12","author":"M Li","year":"2025","unstructured":"Li M, Cai M, Lv H, Zhou S-L, Zhu Y, Shui R-H, et al. Illuminating the clinicopathological and genomic landscape of HER2-null, ultralow, and low breast cancers: insights into diagnostic discordance between biopsy and surgical excision. NPJ Breast Cancer. 2025;12(1):17. https:\/\/doi.org\/10.1038\/s41523-025-00882-0.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"4508_CR58","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","volume":"16","author":"L-C Tsao","year":"2025","unstructured":"Tsao L-C, Wang JSX, Sodhi S, Ragusa JV, Liu B, McBane J, et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat Commun. 2025;16(1):3167. https:\/\/doi.org\/10.1038\/s41467-025-58266-8.","journal-title":"Nat Commun"},{"key":"4508_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00872-2","author":"Y-H Dong","year":"2025","unstructured":"Dong Y-H, Xu Y-T, Jiang X, Xu L, Yu R-J, Wang R, et al. HER2-low and ultralow expression of invasive breast carcinoma: clinicopathological features and immunohistochemical consistency analysis. NPJ Breast Cancer. 2025. https:\/\/doi.org\/10.1038\/s41523-025-00872-2.","journal-title":"NPJ Breast Cancer"},{"key":"4508_CR60","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41571-025-01016-y","volume":"22","author":"CJ Robbins","year":"2025","unstructured":"Robbins CJ, Bates KM, Rimm D. HER2 testing: evolution and update for a companion diagnostic assay. Nat Rev Clin Oncol. 2025;22:408\u201323. https:\/\/doi.org\/10.1038\/s41571-025-01016-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"4508_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2025.105818","author":"M Marabi","year":"2025","unstructured":"Marabi M, Tse GM. Best pathology practices for HER2 testing interpretation, including HER2-low and ultralow, in the era of HER2-directed antibody drug conjugates (ADCs), aligned with the 2018 CAP\/ASCO HER2 guidelines. Hum Pathol. 2025. https:\/\/doi.org\/10.1016\/j.humpath.2025.105818.","journal-title":"Hum Pathol"},{"key":"4508_CR62","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4274\/ejbh.galenos.2025.2024-10-2","volume":"21","author":"A Dogra","year":"2025","unstructured":"Dogra A, Prakash A, Gupta S, Gupta M. Prognostic significance and molecular classification of triple negative breast cancer: a systematic review. Eur J Breast Health. 2025;21:101\u201314. https:\/\/doi.org\/10.4274\/ejbh.galenos.2025.2024-10-2.","journal-title":"Eur J Breast Health"},{"key":"4508_CR63","doi-asserted-by":"publisher","DOI":"10.21037\/tbcr-24-33","author":"J Shang","year":"2024","unstructured":"Shang J, Liu Y. Pathological precision diagnosis and recent advances in HER2 low and ultralow in breast cancer: a narrative review. Transl Breast Cancer Res. 2024. https:\/\/doi.org\/10.21037\/tbcr-24-33.","journal-title":"Transl Breast Cancer Res"},{"key":"4508_CR64","doi-asserted-by":"publisher","first-page":"102865","DOI":"10.1016\/j.ctrv.2024.102865","volume":"132","author":"F Schettini","year":"2024","unstructured":"Schettini F, Nucera S, Pascual T, Mart\u00ednez-S\u00e1ez O, S\u00e1nchez-Bayona R, Conte B, et al. Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: a systematic review and network meta-analysis. Cancer Treat Rev. 2024;132:102865. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102865.","journal-title":"Cancer Treat Rev"},{"key":"4508_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25021318","author":"Y Tsai","year":"2024","unstructured":"Tsai Y, Huang C-C, Hsu C-Y, Feng C-J, Lin Y-S, Chao T-C, et al. Genomic alterations of tumors in HER2-low breast cancers. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25021318.","journal-title":"Int J Mol Sci"},{"key":"4508_CR66","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10549-025-07759-7","volume":"213","author":"R Chaubal","year":"2025","unstructured":"Chaubal R, Talker E, Chitra J, Kadam R, Gardi N, Ursekar R, et al. Genomic landscape of hormone therapy-resistant HR-positive, HER2-negative breast cancer. Breast Cancer Res Treat. 2025;213:247\u201359. https:\/\/doi.org\/10.1007\/s10549-025-07759-7.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"4508_CR67","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1309\/AJCPT41TCBUEVDQC","volume":"144","author":"D Furrer","year":"2015","unstructured":"Furrer D, Sanschagrin F, Jacob S, Diorio C. Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens. Am J Clin Pathol. 2015;144(5):686\u2013703. https:\/\/doi.org\/10.1309\/AJCPT41TCBUEVDQC.","journal-title":"Am J Clin Pathol"},{"key":"4508_CR68","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs21-p4-05-09","author":"H Zhang","year":"2022","unstructured":"Zhang H, Katerji H, Turner B, Hicks D. Abstract P4\u201305-09: clinicopathologic characteristics and molecular profiling of HER2-low breast cancer: a single academic institution experience. Cancer Res. 2022. https:\/\/doi.org\/10.1158\/1538-7445.sabcs21-p4-05-09.","journal-title":"Cancer Res"},{"key":"4508_CR69","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/cancers18040657","volume":"18","author":"F Ultimescu","year":"2026","unstructured":"Ultimescu F, Ardeleanu C, Ginghina O, Mardare M, Zamfir M, Pu\u015fca\u015fu A, et al. From static to dynamic: adaptive molecular subtyping in treated breast cancers-evidence from single-center retrospective cohort study. Cancers. 2026;18:4. https:\/\/doi.org\/10.3390\/cancers18040657.","journal-title":"Cancers"},{"key":"4508_CR70","doi-asserted-by":"publisher","DOI":"10.2147\/bctt.s558033","volume":"18","author":"R Ye","year":"2026","unstructured":"Ye R, Dai X, Yang Z, Zhang D, Hu Z, Liao Y, et al. Clonal dynamics and molecular heterogeneity of metaplastic breast cancer: focus on TP53 and PIK3CA truncal mutations. Breast Cancer (Auckl). 2026;18:558033. https:\/\/doi.org\/10.2147\/bctt.s558033.","journal-title":"Breast Cancer (Auckl)"},{"key":"4508_CR71","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","volume":"187","author":"A Passaro","year":"2024","unstructured":"Passaro A, Bakir AM, Hamilton EG, Diehn M, Andr\u00e9 F, Roy-Chowdhuri S, et al. Cancer biomarkers - emerging trends and clinical implications for personalized treatment. Cell. 2024;187:1617\u201335. https:\/\/doi.org\/10.1016\/j.cell.2024.02.041.","journal-title":"Cell"},{"key":"4508_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2026.104111","author":"MN Park","year":"2026","unstructured":"Park MN, Kim HJ, Park S, Syahputra RA, Delfino DV, Ko S-G, et al. A clinical decision framework for redox-adapted, EMT-high cancers: from ferroptosis resistance to precision therapeutic stratification. Redox Biol. 2026. https:\/\/doi.org\/10.1016\/j.redox.2026.104111.","journal-title":"Redox Biol"},{"key":"4508_CR73","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2022-0335-ra","author":"G Tozbikian","year":"2023","unstructured":"Tozbikian G, Krishnamurthy S, Bui M, Feldman M, Hicks D, Jaffer S, et al. Emerging landscape of targeted therapy of breast cancers with low HER2 protein expression. Arch Pathol Lab Med. 2023. https:\/\/doi.org\/10.5858\/arpa.2022-0335-ra.","journal-title":"Arch Pathol Lab Med"},{"key":"4508_CR74","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqab117","author":"H Zhang","year":"2021","unstructured":"Zhang H, Katerji H, Turner B, Hicks D. HER2-low breast cancers. Am J Clin Pathol. 2021. https:\/\/doi.org\/10.1093\/ajcp\/aqab117.","journal-title":"Am J Clin Pathol"},{"key":"4508_CR75","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41379-022-01019-5","volume":"35","author":"H Zhang","year":"2022","unstructured":"Zhang H, Katerji H, Turner B, Audeh W, Hicks D. HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles. Mod Pathol. 2022;35:1075\u201382. https:\/\/doi.org\/10.1038\/s41379-022-01019-5.","journal-title":"Mod Pathol"},{"issue":"4","key":"4508_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100087","volume":"36","author":"X Baez-Navarro","year":"2023","unstructured":"Baez-Navarro X, van Bockstal M, Andrinopoulou E, van Deurzen C. HER2-low breast cancer: incidence, clinicopathologic features, and survival outcomes from real-world data of a large nationwide cohort. Mod Pathol. 2023;36(4):100087. https:\/\/doi.org\/10.1016\/j.modpat.2022.100087.","journal-title":"Mod Pathol"},{"key":"4508_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39372-3","author":"M Yang","year":"2023","unstructured":"Yang M, Sun J, Liu L, Kong X, Lin D, Zhou H, et al. Clinicopathological characteristics of HER2-low breast cancer: a retrospective study. Sci Rep. 2023. https:\/\/doi.org\/10.1038\/s41598-023-39372-3.","journal-title":"Sci Rep"},{"issue":"1","key":"4508_CR78","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12957-024-03530-2","volume":"22","author":"S Yan","year":"2024","unstructured":"Yan S, Zhao W, Dong Y, Wang H, Xu S, Yu T, et al. Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterations. World J Surg Oncol. 2024;22(1):248. https:\/\/doi.org\/10.1186\/s12957-024-03530-2.","journal-title":"World J Surg Oncol"},{"issue":"11","key":"4508_CR79","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.3390\/cancers16112009","volume":"16","author":"C Andr\u00e9","year":"2024","unstructured":"Andr\u00e9 C, Bertaut A, Ladoire S, Desmoulins I, Jankowski C, Beltjens F, et al. HER2-low luminal breast carcinoma is not a homogenous clinicopathological and molecular entity. Cancers. 2024;16(11):2009. https:\/\/doi.org\/10.3390\/cancers16112009.","journal-title":"Cancers"},{"issue":"4","key":"4508_CR80","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1208\/s12249-026-03425-3","volume":"27","author":"A Shadab","year":"2026","unstructured":"Shadab A, Haider MF, Abohassan M. Liposome-based drug delivery systems: mechanisms, preparation strategies, clinical status, and therapeutic applications. AAPS PharmSciTech. 2026;27(4):190. https:\/\/doi.org\/10.1208\/s12249-026-03425-3.","journal-title":"AAPS PharmSciTech"},{"issue":"10","key":"4508_CR81","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3390\/cancers16101801","volume":"16","author":"M Grammoustianou","year":"2024","unstructured":"Grammoustianou M, Dimitrakopoulos F, Koutras A. Current status and future perspectives of antibody-drug conjugates in hormone receptor-positive breast cancer. Cancers. 2024;16(10):1801. https:\/\/doi.org\/10.3390\/cancers16101801.","journal-title":"Cancers"},{"key":"4508_CR82","doi-asserted-by":"publisher","first-page":"22","DOI":"10.20517\/cdr.2024.06","volume":"7","author":"K Saleh","year":"2024","unstructured":"Saleh K, Khoury R, Khalife N, Chahine C, Ibrahim R, Tikriti Z, et al. Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer. Cancer Drug Resist. 2024;7:22. https:\/\/doi.org\/10.20517\/cdr.2024.06.","journal-title":"Cancer Drug Resist"},{"key":"4508_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113371","volume":"195","author":"N Atallah","year":"2023","unstructured":"Atallah N, Haque M, Quinn C, Toss M, Makhlouf S, Ibrahim A, et al. Characterisation of luminal and triple-negative breast cancer with HER2 low protein expression. Eur J Cancer. 2023;195:113371. https:\/\/doi.org\/10.1016\/j.ejca.2023.113371.","journal-title":"Eur J Cancer"},{"key":"4508_CR84","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs22-her2-12","author":"R Bansal","year":"2023","unstructured":"Bansal R, McGrath J, Walker P, Bustos M, Rodriguez E, Sammons S, et al. Abstract HER2-12: genomic and transcriptomic landscape of HER2-low breast cancer. Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1538-7445.sabcs22-her2-12.","journal-title":"Cancer Res"},{"key":"4508_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-0151-5","author":"F Bertucci","year":"2020","unstructured":"Bertucci F, Finetti P, Gon\u00e7alves A, Birnbaum D. The therapeutic response of ER+\/HER2\u2212 breast cancers differs according to the molecular Basal or Luminal subtype. NPJ Breast Cancer. 2020. https:\/\/doi.org\/10.1038\/s41523-020-0151-5.","journal-title":"NPJ Breast Cancer"},{"key":"4508_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1340764","author":"L-Q Cao","year":"2024","unstructured":"Cao L-Q, Sun H, Xie Y, Patel H, Bo L, Lin H, et al. Therapeutic evolution in HR+\/HER2- breast cancer: from targeted therapy to endocrine therapy. Front Pharmacol. 2024. https:\/\/doi.org\/10.3389\/fphar.2024.1340764.","journal-title":"Front Pharmacol"},{"key":"4508_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071102","author":"E Carvalho","year":"2025","unstructured":"Carvalho E, Canberk \u015e, Schmitt F, Vale N. Molecular subtypes and mechanisms of breast cancer: precision medicine approaches for targeted therapies. Cancers. 2025. https:\/\/doi.org\/10.3390\/cancers17071102.","journal-title":"Cancers"},{"key":"4508_CR88","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs22-p1-11-06","author":"L Chen","year":"2023","unstructured":"Chen L, Liu C-C, Ge J-Y, Shao Z, Yu K. Abstract P1-11-06: multi-omics profiling of HER2-low breast cancer reveals clinically relevant subgroups and therapeutic pathways. Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1538-7445.sabcs22-p1-11-06.","journal-title":"Cancer Res"},{"key":"4508_CR89","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs23-po4-14-08","author":"S Cosimo","year":"2024","unstructured":"Cosimo S, Pizzamiglio S, Ciniselli C, Duroni V, Cappelletti V, de Cecco L, et al. Abstract PO4-14-08: a gene expression-based classifier for HER2-low breast cancer. Can Res. 2024. https:\/\/doi.org\/10.1158\/1538-7445.sabcs23-po4-14-08.","journal-title":"Can Res"},{"key":"4508_CR90","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2025-2690","author":"M Cumberbatch","year":"2025","unstructured":"Cumberbatch M, Kim WH, Bhagat M, Cogswell J. Abstract 2690: expression profiles of antibody drug conjugate (ADC) targets in breast and lung cancer subtypes and in new HER2 subgroups with their PD-L1 status. Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1538-7445.am2025-2690.","journal-title":"Cancer Res"},{"key":"4508_CR91","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs22-her2-06","author":"C Denkert","year":"2023","unstructured":"Denkert C, Mart\u00edn M, Untch M, Bonnefoi H, Knudsen E, Im S, et al. Abstract HER2\u201306: outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR+) breast cancer patients. Can Res. 2023. https:\/\/doi.org\/10.1158\/1538-7445.sabcs22-her2-06.","journal-title":"Can Res"},{"key":"4508_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52148-7","author":"S di Cosimo","year":"2024","unstructured":"di Cosimo S, Pizzamiglio S, Ciniselli C, Duroni V, Cappelletti V, de Cecco L, et al. A gene expression-based classifier for HER2-low breast cancer. Sci Rep. 2024. https:\/\/doi.org\/10.1038\/s41598-024-52148-7.","journal-title":"Sci Rep"},{"key":"4508_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102496","volume":"112","author":"C Falato","year":"2022","unstructured":"Falato C, Schettini F, Pascual T, Bras\u00f3-Maristany F, Prat A. Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. Cancer Treat Rev. 2022;112:102496. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102496.","journal-title":"Cancer Treat Rev"},{"key":"4508_CR94","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2025.2898","author":"A Georgiou","year":"2025","unstructured":"Georgiou A, Spiteri EA, Spandidos D, Agelaki S, Zoumpourlis V. Taking the \u2018low\u2019 into consideration: discussions on redefining HER2 status in breast cancer (Review). Mol Clin Oncol. 2025. https:\/\/doi.org\/10.3892\/mco.2025.2898.","journal-title":"Mol Clin Oncol"},{"key":"4508_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216763","author":"B-Y Han","year":"2024","unstructured":"Han B-Y, Chen C, Luo H, Lin C-J, Han X, Nasir J, et al. Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-low breast cancer. Cancer Lett. 2024. https:\/\/doi.org\/10.1016\/j.canlet.2024.216763.","journal-title":"Cancer Lett"},{"key":"4508_CR96","doi-asserted-by":"publisher","first-page":"11","DOI":"10.18632\/oncotarget.28680","volume":"16","author":"WL Hensing","year":"2025","unstructured":"Hensing WL, Podany E, Sears J, Tapiavala S, Davis A. Evolving concepts in HER2-low breast cancer: genomic insights, definitions, and treatment paradigms. Oncotarget. 2025;16:11\u201327. https:\/\/doi.org\/10.18632\/oncotarget.28680.","journal-title":"Oncotarget"},{"key":"4508_CR97","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad159","author":"T Hui","year":"2023","unstructured":"Hui T, Li S, Wang H, Xuejiao D, Gao F, Yang W, et al. An analysis of clinical and pathologic features, recurindex genomic profiles, and survival outcomes in HER2-low breast cancer. Oncol. 2023. https:\/\/doi.org\/10.1093\/oncolo\/oyad159.","journal-title":"Oncol"},{"key":"4508_CR98","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/s41588-023-01507-7","volume":"55","author":"X Jin","year":"2023","unstructured":"Jin X, Zhou Y-F, Zhao S, Lin C-J, Xiao Y, Fu T, et al. Molecular classification of hormone receptor-positive HER2-negative breast cancer. Nat Genet. 2023;55:1696\u2013708. https:\/\/doi.org\/10.1038\/s41588-023-01507-7.","journal-title":"Nat Genet"},{"key":"4508_CR99","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.1027","author":"J Juan","year":"2023","unstructured":"Juan J, Li B, Wang B, Tao Z, Hu X. Clinical features, genomic landscapes, and survival outcomes of HER2-low breast cancer. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/jco.2023.41.16_suppl.1027.","journal-title":"J Clin Oncol"},{"key":"4508_CR100","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs23-po4-15-08","author":"A Kahn","year":"2024","unstructured":"Kahn A, Sokol E, Ross J, Pelletier M, Fischbach N, Pusztai L, et al. Abstract PO4-15-08: comprehensive genomic profiling of HER2-low advanced breast cancers. Cancer Res. 2024. https:\/\/doi.org\/10.1158\/1538-7445.sabcs23-po4-15-08.","journal-title":"Cancer Res"},{"key":"4508_CR101","doi-asserted-by":"publisher","first-page":"11","DOI":"10.20517\/cdr.2024.180","volume":"8","author":"\u00c9A Larose","year":"2025","unstructured":"Larose \u00c9A, Hua X, Yu S, Pillai AT, Yi Z, Yu H. Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing. Cancer Drug Resist. 2025;8:11. https:\/\/doi.org\/10.20517\/cdr.2024.180.","journal-title":"Cancer Drug Resist"},{"key":"4508_CR102","doi-asserted-by":"publisher","first-page":"59","DOI":"10.20517\/cdr.2025.148","volume":"8","author":"Y Hao","year":"2025","unstructured":"Hao Y, Song Z. Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies. Cancer Drug Resist. 2025;8:59. https:\/\/doi.org\/10.20517\/cdr.2025.148.","journal-title":"Cancer Drug Resist"},{"key":"4508_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00239-2","author":"Y Gu","year":"2025","unstructured":"Gu Y, Yang R-F, Zhang Y, Guo M, Takehiro K, Zhan M, et al. Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer. Mol Biomed. 2025. https:\/\/doi.org\/10.1186\/s43556-024-00239-2.","journal-title":"Mol Biomed"},{"key":"4508_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105179","author":"X Wen","year":"2026","unstructured":"Wen X, Wang W, Song J, Chen M, Xue W, Lin D, et al. Resistance mechanisms and post-trastuzumab deruxtecan (T-DXd) strategies in HER2+ and HER2-low breast cancer: from biology to clinical practice. Crit Rev Oncol Hematol. 2026. https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105179.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4508_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152635","author":"A Cai","year":"2024","unstructured":"Cai A, Chen Y, Wang LS, Cusick JK, Shi Y. Depicting biomarkers for HER2-inhibitor resistance: implication for therapy in HER2-positive breast cancer. Cancers. 2024. https:\/\/doi.org\/10.3390\/cancers16152635.","journal-title":"Cancers"},{"key":"4508_CR106","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2459458","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Fan W, Su F, Zhang X, Du Y, Li W, et al. Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy. Hum Vaccines Immunother. 2025. https:\/\/doi.org\/10.1080\/21645515.2025.2459458.","journal-title":"Hum Vaccines Immunother"},{"key":"4508_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67865-4","author":"L Luo","year":"2026","unstructured":"Luo L, Wang Y, Bui TN, Jiang X-T, Chen M-K, Rao X, et al. CDK2 inhibitor BLU-222 synergizes with CDK4\/6 inhibitors in drug resistant breast cancers through p21\/p27 induction. Nat Commun. 2026. https:\/\/doi.org\/10.1038\/s41467-025-67865-4.","journal-title":"Nat Commun"},{"key":"4508_CR108","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.e13148","author":"MA Khalil","year":"2024","unstructured":"Khalil MA, Habibian L, Martin C, Semaan K, Khaddage A, Kassis E, et al. Landscape of HER2-low breast cancer: Insights from a six-year study on incidence and clinicopathological characteristics. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.e13148.","journal-title":"J Clin Oncol"},{"key":"4508_CR109","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.e12546","author":"Y-J Lee","year":"2025","unstructured":"Lee Y-J, Lee S, Lee HJ, Yoo T, Kim J, Chung I, et al. Re-evaluation of HER2 status and prognostic implications of ultra-low and low HER2 expression in estrogen receptor\u2013positive breast cancer. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/jco.2025.43.16_suppl.e12546.","journal-title":"J Clin Oncol"},{"key":"4508_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30143026","author":"J Li","year":"2025","unstructured":"Li J, Li X, Fu R, Fang Y, Zhang C, Bingbing D, et al. Recent research advances in HER2-positive breast cancer concerning targeted therapy drugs. Mol. 2025. https:\/\/doi.org\/10.3390\/molecules30143026.","journal-title":"Mol"},{"key":"4508_CR111","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-23-4066","author":"Y-W Li","year":"2024","unstructured":"Li Y-W, Dai L, Wu X-R, Zhao S, Xu Y-Z, Jin X, et al. Molecular characterization and classification of HER2-positive breast cancer inform tailored therapeutic strategies. Cancer Res. 2024. https:\/\/doi.org\/10.1158\/0008-5472.can-23-4066.","journal-title":"Cancer Res"},{"key":"4508_CR112","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs23-ps09-09","author":"Y-W Li","year":"2024","unstructured":"Li Y-W, Wu X-R, Dai L, Zhao S, Xu Y-Z, Jin X, et al. Abstract PS09-09: multiomics profiling and molecular classification refine precision treatment strategies for HER2-positive breast cancer. Cancer Res. 2024. https:\/\/doi.org\/10.1158\/1538-7445.sabcs23-ps09-09.","journal-title":"Cancer Res"},{"key":"4508_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02181-3","author":"C Liu","year":"2025","unstructured":"Liu C, Sun L, Niu N, Hou P, Chen G, Wang H, et al. Molecular classification of hormone receptor-positive \/HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategies. Signal Transduct Target Ther. 2025. https:\/\/doi.org\/10.1038\/s41392-025-02181-3.","journal-title":"Signal Transduct Target Ther"},{"key":"4508_CR114","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41571-023-00849-9","volume":"21","author":"A Marra","year":"2024","unstructured":"Marra A, Chandarlapaty S, Modi S. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. Nat Rev Clin Oncol. 2024;21:185\u2013202. https:\/\/doi.org\/10.1038\/s41571-023-00849-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"4508_CR115","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs22-her2-07","author":"A Marra","year":"2023","unstructured":"Marra A, Safonov A, Drago J, Ferraro E, Selenica P, Gazzo A, et al. Abstract HER2-07: genomic characterization of primary and metastatic HER2-low breast cancers. Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1538-7445.sabcs22-her2-07.","journal-title":"Cancer Res"},{"key":"4508_CR116","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071987","author":"M Mercogliano","year":"2023","unstructured":"Mercogliano M, Bruni S, Mauro F, Schillaci R. Emerging targeted therapies for HER2-positive breast cancer. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15071987.","journal-title":"Cancers"},{"key":"4508_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00343-4","author":"F Miglietta","year":"2021","unstructured":"Miglietta F, Griguolo G, Bottosso M, Giarratano T, lo Mele M, Fassan M, et al. Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer. 2021. https:\/\/doi.org\/10.1038\/s41523-021-00343-4.","journal-title":"NPJ Breast Cancer"},{"key":"4508_CR118","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf081","author":"G Munk\u00e1csy","year":"2025","unstructured":"Munk\u00e1csy G, Santarpia L, Gy\u0151rffy B. Exploring immune activation patterns in HER2-low and HER2-ultralow breast cancer subtypes. Oncol. 2025. https:\/\/doi.org\/10.1093\/oncolo\/oyaf081.","journal-title":"Oncol"},{"issue":"12","key":"4508_CR119","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3390\/pharmaceutics17121581","volume":"17","author":"H Jang","year":"2025","unstructured":"Jang H, Chang JE. Strategic combinations of antibody-drug conjugates from 2023 to 2025: from dual therapies to innovative ADC-based regimens. Pharmaceutics. 2025;17(12):1581. https:\/\/doi.org\/10.3390\/pharmaceutics17121581.","journal-title":"Pharmaceutics"},{"key":"4508_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54621-3","author":"M Rediti","year":"2024","unstructured":"Rediti M, Venet D, Garcia J, Maetens M, Vincent D, Majjaj S, et al. Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial. Nat Commun. 2024. https:\/\/doi.org\/10.1038\/s41467-024-54621-3.","journal-title":"Nat Commun"},{"key":"4508_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20051115","author":"G Rinnerthaler","year":"2019","unstructured":"Rinnerthaler G, Gampenrieder S, Greil R. HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20051115.","journal-title":"Int J Mol Sci"},{"key":"4508_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.05.005","author":"D Wolf","year":"2022","unstructured":"Wolf D, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher I, Lee P, et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022. https:\/\/doi.org\/10.1016\/j.ccell.2022.05.005.","journal-title":"Cancer Cell"},{"key":"4508_CR123","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.breast.2021.07.019","volume":"59","author":"F Schettini","year":"2021","unstructured":"Schettini F, Prat A. Dissecting the biological heterogeneity of HER2-positive breast cancer. Breast. 2021;59:339\u201350. https:\/\/doi.org\/10.1016\/j.breast.2021.07.019.","journal-title":"Breast"},{"key":"4508_CR124","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-01969-z","author":"G Schmidt","year":"2025","unstructured":"Schmidt G, Gluz O, Christgen M, Reinisch M, K\u00fcmmel S, Nitz U, et al. HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+\/HER2-, WSG-PlanB, and WSG-ADAPT-TN. Breast Cancer Res. 2025. https:\/\/doi.org\/10.1186\/s13058-025-01969-z.","journal-title":"Breast Cancer Res"},{"issue":"9","key":"4508_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103679","volume":"9","author":"K Shimozaki","year":"2024","unstructured":"Shimozaki K, Fukuoka S, Ooki A, Yamaguchi K. HER2-low gastric cancer: is the subgroup targetable? ESMO Open. 2024;9(9):103679. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103679.","journal-title":"ESMO Open"},{"key":"4508_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030548","author":"V Silvestri","year":"2024","unstructured":"Silvestri V, Valentini V, Bucalo A, Conti G, Manzella L, Turchetti D, et al. HER2-low expression in male breast cancer: results from a multicenter series in Italy. Cancers. 2024. https:\/\/doi.org\/10.3390\/cancers16030548.","journal-title":"Cancers"},{"key":"4508_CR127","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs23-po4-02-02","author":"A Sivapiragasam","year":"2024","unstructured":"Sivapiragasam A, Brufsky A, Linden H, Hunter N, Osborne C, Diab S, et al. Abstract PO4-02-02: genomic landscape of ER positive HER2-low early breast cancers in the FLEX study. Cancer Res. 2024. https:\/\/doi.org\/10.1158\/1538-7445.sabcs23-po4-02-02.","journal-title":"Cancer Res"},{"key":"4508_CR128","doi-asserted-by":"publisher","DOI":"10.1007\/s12609-026-00655-z","volume":"18","author":"A Shadab","year":"2026","unstructured":"Shadab A, Al-Shdefat R. Neurocognitive dysfunction (\u2018chemo brain\u2019) in breast cancer survivors: mechanisms and emerging therapeutic strategies. Curr Breast Cancer Rep. 2026;18:28. https:\/\/doi.org\/10.1007\/s12609-026-00655-z.","journal-title":"Curr Breast Cancer Rep"},{"key":"4508_CR129","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs22-her2-05","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Gupta H, Hughes M, Files J, Strauss S, Kirkner G, et al. Abstract HER2\u201305: Comprehensive genomic characterization of HER2-low breast cancer. Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1538-7445.sabcs22-her2-05.","journal-title":"Cancer Res"},{"key":"4508_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00723-0","author":"P Turova","year":"2025","unstructured":"Turova P, Kushnarev V, Baranov O, Butusova A, Menshikova S, Yong S, et al. The breast cancer classifier refines molecular breast cancer classification to delineate the HER2-low subtype. NPJ Breast Cancer. 2025. https:\/\/doi.org\/10.1038\/s41523-025-00723-0.","journal-title":"NPJ Breast Cancer"},{"key":"4508_CR131","doi-asserted-by":"publisher","first-page":"252","DOI":"10.15252\/embj.201695204","volume":"36","author":"GL Semenza","year":"2017","unstructured":"Semenza GL. Hypoxia\u2010inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype. EMBO J. 2017;36:252\u20139. https:\/\/doi.org\/10.15252\/embj.201695204.","journal-title":"EMBO J"},{"key":"4508_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102689","author":"I Voutsadakis","year":"2023","unstructured":"Voutsadakis I. Comparison of clinical subtypes of breast cancer within the claudin-low molecular cluster reveals distinct phenotypes. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15102689.","journal-title":"Cancers"},{"key":"4508_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02346-9","author":"G Zhang","year":"2022","unstructured":"Zhang G, Ren C, Li C, Wang Y, Chen B, Wen L, et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status. BMC Med. 2022. https:\/\/doi.org\/10.1186\/s12916-022-02346-9.","journal-title":"BMC Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04508-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04508-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04508-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T18:22:06Z","timestamp":1784658126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04508-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":133,"alternative-id":["4508"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04508-0","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No AI tool was used for data generation, data analysis, fabrication or manipulation of results, or creation of tables, figures, or scientific content. All scientific interpretations, data, and conclusions presented in this work are entirely the responsibility of the authors.","order":4,"name":"Ethics","label":"AI generative statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}